Combination therapy improves survival outcomes in advanced renal-cell carcinoma
In short: In a phase 3 randomized trial of 651 adults, researchers found that combining nivolumab and cabozantinib significantly extended progression-free survival compared to sunitinib for those with previously untreated, advanced clear-cell renal-cell carcinoma. The combination therapy also showed higher rates of tumor response and better reported health-related quality of life.
The study compared the combination of nivolumab and cabozantinib against sunitinib in a randomized, open-label design. While the results showed significant benefits in survival and response rates, the trial was open-label, meaning both patients and clinicians knew which treatment was being administered.
The researchers observed a median progression-free survival of 16.6 months for the combination group versus 8.3 months for the sunitinib group.
Why it matters: A new combination therapy offers superior survival and response benefits for advanced renal-cell carcinoma patients.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Choueiri et al. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-combination-therapy-improves-survival-outcomes-in-advanced-r.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
